Phase II trial evaluating the long-term efficacy and peripheral sensory neuropathy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer
Taishi Hata(The University of Osaka), Hidetoshi Eguchi(Osaka Gakuin University), Shu Okamura(Suita Municipal Hospital), Yoshinori Kagawa(Osaka International Cancer Institute), Yuichiro� Doki(Osaka Gakuin University), Tsukasa Tanida, Takamichi Komori(Osaka International Cancer Institute), Shinichi Yoshioka(Yao Tokushukai General Hospital), Katsuki Danno(The University of Osaka), Hirofumi Ota(Japan Society of Laparoscopic Colorectal Surgery), Takayuki Ogino(The University of Osaka), Mitsuyoshi Tei(Osaka Rosai Hospital), Chu Matsuda(Osaka International Cancer Institute), Mamoru Uemura(The University of Osaka), Hiroyoshi Takemoto(Kinki Central Hospital), Norikatsu Miyoshi(The University of Osaka), Hirofumi Yamamoto(The University of Osaka), Tatsushi Shingai(Kinki Central Hospital), Kohei Murata(Suita Municipal Hospital), Yozo Suzuki(Osaka Police Hospital)
Cited by 0
Related Papers
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
|Nature Medicine|2020|366
Overexpression of miR-200c Induces Chemoresistance in Esophageal Cancers Mediated Through Activation of the Akt Signaling Pathway
|Clinical Cancer Research|2011|245
Implications of Nectin-like Molecule-2/IGSF4/RA175/SgIGSF/TSLC1/SynCAM1 in Cell-Cell Adhesion and Transmembrane Protein Localization in Epithelial Cells
|Journal of Biological Chemistry|2003|231